Coagulation Studies and Platelet Function After Somatostatin Infusion

Overview

Journal Klin Wochenschr

Specialty General Medicine

Date 1976 Oct 15

PMID 979078

Authors

H Rasche

S Raptis

R Scheck

E F Pfeiffer

Affiliations

Soon will be listed here.

Abstract

The effect of short- and long-term somatostatin (GIF) administration on haemostatic function in man was investigated. The dosage programme applied in this study was 250 mug GIF as a bolus injection and 250 mug GIF/h by way of infusion. In five healthy volunteers a short-term (3h) treatment resulted in a statistically significant drop of platelet count and impairment of platelet aggregation at the end of infusion. However, these changes were within the physiologically normal range and disappeared after two hours on all subjects. Other parameters such as bleeding time, thromboplastin and partial thromboplastin time, fibrinogen, fibrin/fibrinogen split products, plasma factor XIII, ethanol gelation test were not affected. In two patients with gastric haemorrhage and persistent amylasaemia a 67 or 120-h treatment induced no remarkable haemostatic defect. By contrast, peptic ulcer bleeding in one patient stopped 60 min after starting the GIF infusion. These studies indicated that somatostatin administration in man at the dosage programme used neither results in clinical evidence indicating bleeding tendency nor does it influence laboratory parameters in an apparent way.

References

Gerich J, Lorenzi M, Schneider V, FORSHAM P . Effect of somatostatin on plasma glucose and insulin responses to glucagon and tolbutamide in man. J Clin Endocrinol Metab. 1974; 39(6):1057-60. DOI: 10.1210/jcem-39-6-1057. View

Yen S, Siler T, DeVane G . Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels. N Engl J Med. 1974; 290(17):935-8. DOI: 10.1056/NEJM197404252901704. View

Creutzfeldt W, Lankisch P, Folsch U . [Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction in man induced by secretin and cholecystokinin-pancreozymin administration (author's transl)]. Dtsch Med Wochenschr. 1975; 100(20):1135-8. View

Gerich J, Lorenzi M, Schneider V, Kwan C, KARAM J, Guillemin R . Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics. Diabetes. 1974; 23(11):876-80. DOI: 10.2337/diab.23.11.876. View

TRIANTAPHYLLOPOULOS D . Factor XIII consumption as an indicator of thrombin generation. J Lab Clin Med. 1974; 84(1):74-80. View

Meissner C, Thum C, Beischer W, Winkler G, Schroder K, Pfeiffer E . Antidiabetic action of somatostatin--assessed by the artificial pancreas. Diabetes. 1975; 24(11):988-96. DOI: 10.2337/diab.24.11.988. View

Mortimer C, Tunbridge W, Carr D, Yeomans L, Lind T, Coy D . Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet. 1974; 1(7860):697-701. DOI: 10.1016/s0140-6736(74)92903-1. View

Gerich J, Lorenzi M, Bier D, Schneider V, Tsalikian E, KARAM J . Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med. 1975; 292(19):985-9. DOI: 10.1056/NEJM197505082921901. View

Chiang T, Duckworth W, Beachey E, Kang A . The effect of somatostatin on platelet aggregation. Endocrinology. 1975; 97(3):753-6. DOI: 10.1210/endo-97-3-753. View

10.

MERSKEY C, Kleiner G, Johnson A . Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood. 1966; 28(1):1-18. View

11.

Sakurai H, DOBBS R, Unger R . Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs. J Clin Invest. 1974; 54(6):1395-402. PMC: 301694. DOI: 10.1172/JCI107886. View

12.

Parker D, Rossman L, Siler T, Rivier J, Yen S, Guillemin R . Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin. J Clin Endocrinol Metab. 1974; 38(3):496-9. DOI: 10.1210/jcem-38-3-496. View

13.

Benker G, REINWEIN D . [Somatostatin--effects and possible clinical significance]. Dtsch Med Wochenschr. 1975; 100(17):961-4. DOI: 10.1055/s-0028-1106322. View

14.

Bloom S, Mortimer C, Thorner M, Besser G, Hall R, Gomez-Pan A . Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet. 1974; 2(7889):1106-9. DOI: 10.1016/s0140-6736(74)90869-1. View

15.

Mielke Jr C, Kaneshiro M, Maher I, Weiner J, RAPAPORT S . The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969; 34(2):204-15. View

16.

COPINSCHI G, Virasoro E, Vanhaelst L, Leclercq R, Golstein J, LHermite M . Specific inhibition by somatostatin of growth hormone release after hypoglycaemia in normal man. Clin Endocrinol (Oxf). 1974; 3(4):411-5. DOI: 10.1111/j.1365-2265.1974.tb02815.x. View

17.

Clauss A . [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol. 1957; 17(4):237-46. DOI: 10.1159/000205234. View

18.

Koerker D, Harker L, GOODNER C . Effects of somatostatin on hemostasis in baboons. N Engl J Med. 1975; 293(10):476-9. DOI: 10.1056/NEJM197509042931004. View

19.

Born G . Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962; 194:927-9. DOI: 10.1038/194927b0. View

20.

Hall R, Besser G, Schally A, Coy D, Evered D, Goldie D . Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet. 1973; 2(7829):581-4. DOI: 10.1016/s0140-6736(73)92413-6. View